Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

Researchers analyzed the thermodynamics of doxepin binding to the histamine H1 receptor. The findings highlight the ...

Septerna wants to spark a second golden age in G-protein-coupled receptor drug discovery. Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous ...

G protein-coupled receptors (GPCRs) remain one of the most pharmacologically successful drug targets, with 35% of all commercial drugs and 19% of newly approved drugs targeting this protein ...

New company established by a leading international life sciences investment firm Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring Monday after the clinical-stage biopharmaceutical company reported positive topline data from a weight loss drug trial. The positive ...

G protein-coupled receptors (GPCRs) are a large family of seven-transmembrane proteins that can be activated by a diverse array of ligands, including hormones, neurotransmitters and sensory stimuli.